These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1952 related articles for article (PubMed ID: 18650835)

  • 1. Modes of resistance to anti-angiogenic therapy.
    Bergers G; Hanahan D
    Nat Rev Cancer; 2008 Aug; 8(8):592-603. PubMed ID: 18650835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The angiogenic process as a therapeutic target in cancer.
    Bridges EM; Harris AL
    Biochem Pharmacol; 2011 May; 81(10):1183-91. PubMed ID: 21382350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling.
    Simon T; Gagliano T; Giamas G
    Trends Mol Med; 2017 Mar; 23(3):282-292. PubMed ID: 28162910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends and Challenges in Tumor Anti-Angiogenic Therapies.
    Jászai J; Schmidt MHH
    Cells; 2019 Sep; 8(9):. PubMed ID: 31540455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redundant angiogenic signaling and tumor drug resistance.
    Gacche RN; Assaraf YG
    Drug Resist Updat; 2018 Jan; 36():47-76. PubMed ID: 29499837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Angiogenics: Current Situation and Future Perspectives.
    Zirlik K; Duyster J
    Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular Detransformation for Cancer Therapy.
    Fan Y
    Trends Cancer; 2019 Aug; 5(8):460-463. PubMed ID: 31421902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.
    Welti J; Loges S; Dimmeler S; Carmeliet P
    J Clin Invest; 2013 Aug; 123(8):3190-200. PubMed ID: 23908119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor angiogenesis and anti-angiogenic therapy.
    Kubota Y
    Keio J Med; 2012; 61(2):47-56. PubMed ID: 22760023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy.
    Elebiyo TC; Rotimi D; Evbuomwan IO; Maimako RF; Iyobhebhe M; Ojo OA; Oluba OM; Adeyemi OS
    Cancer Treat Res Commun; 2022; 32():100620. PubMed ID: 35964475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vessel co-option and resistance to anti-angiogenic therapy.
    Kuczynski EA; Reynolds AR
    Angiogenesis; 2020 Feb; 23(1):55-74. PubMed ID: 31865479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
    Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
    Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
    van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT
    Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.
    Lopes-Coelho F; Martins F; Pereira SA; Serpa J
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of angiogenesis and the angiogenesis/invasion shift.
    Bikfalvi A; Moenner M; Javerzat S; North S; Hagedorn M
    Biochem Soc Trans; 2011 Dec; 39(6):1560-4. PubMed ID: 22103487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor angiogenesis and anti-angiogenic therapies.
    Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
    Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour angiogenesis, anti-angiogenic therapy and chemotherapeutic resistance.
    Mander KA; Finnie JW
    Aust Vet J; 2018 Oct; 96(10):371-378. PubMed ID: 30255577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
    Shinkaruk S; Bayle M; Laïn G; Déléris G
    Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 98.